Bafna Pharmaceuticals Limited Stock Price Today (NSE: BAFNAPH)
Fundamental Score
Bafna Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bafna Pharmaceuticals Limited share price today is ₹309.00, up +0.55% on NSE/BSE as of 16 September 2026. Bafna Pharmaceuticals Limited (BAFNAPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹730.98 (Cr). The 52-week high for BAFNAPH share price is ₹318.50 and the 52-week low is ₹94.77. At a P/E ratio of 93.92x, BAFNAPH is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.27% and a debt-to-equity ratio of 0.39.
Bafna Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Bafna Pharmaceuticals Limited share price chart: 10.12% return over the past month. 52-week high ₹318.50, 52-week low ₹94.77.
Bafna Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹308.10 | ₹309.00 | ₹308.10 | ₹309.00 | 6.54K (Cr) | |
| ₹301.55 | ₹307.45 | ₹301.55 | ₹307.30 | 12.18K (Cr) | |
| ₹301.45 | ₹301.45 | ₹301.45 | ₹301.45 | 11.74K (Cr) | |
| ₹295.60 | ₹307.60 | ₹295.60 | ₹307.60 | 9.24K (Cr) | |
| ₹301.60 | ₹303.10 | ₹301.60 | ₹301.60 | 4.47K (Cr) | |
| ₹307.75 | ₹307.75 | ₹307.75 | ₹307.75 | 6.17K (Cr) | |
| ₹301.75 | ₹301.75 | ₹301.00 | ₹301.75 | 3.08K (Cr) | |
| ₹296.60 | ₹296.60 | ₹295.85 | ₹295.85 | 4.79K (Cr) | |
| ₹307.50 | ₹307.50 | ₹301.85 | ₹301.85 | 4.45K (Cr) | |
| ₹306.35 | ₹308.00 | ₹306.35 | ₹308.00 | 7.53K (Cr) |
Bafna Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹307.00 | ₹318.50 | ₹295.60 | ₹309.00 | +0.65% | |
| ₹268.20 | ₹305.65 | ₹232.95 | ₹304.25 | +13.44% | |
| ₹225.36 | ₹262.91 | ₹200.30 | ₹262.91 | +16.66% | |
| ₹138.00 | ₹214.63 | ₹134.00 | ₹214.63 | +55.53% | |
| ₹133.33 | ₹144.50 | ₹125.00 | ₹131.90 | -1.07% | |
| ₹114.80 | ₹147.95 | ₹109.00 | ₹134.00 | +16.72% | |
| ₹108.00 | ₹126.52 | ₹94.77 | ₹109.34 | +1.24% | |
| ₹118.80 | ₹131.00 | ₹102.01 | ₹106.15 | -10.65% | |
| ₹150.72 | ₹152.50 | ₹109.40 | ₹111.60 | -25.96% | |
| ₹154.28 | ₹173.26 | ₹137.48 | ₹150.72 | -2.31% | |
| ₹150.80 | ₹202.06 | ₹150.79 | ₹151.26 | +0.31% | |
| ₹172.72 | ₹176.25 | ₹132.70 | ₹143.62 | -16.85% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bafna Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bafna Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BAFNAPH across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Consistent Growth Track Record (16.16% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Healthy Liquidity Position (Current Ratio: 1.66)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Premium Valuation Risk (P/E: 93.92x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (7.60x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-97.78%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-23.22%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-16.70 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 9.34%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Bafna Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bafna Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bafna Pharmaceuticals LimitedBafna Pharmaceu...Selected✓ BAFNAPH • 532989 | 39.1/100 | ₹309.00₹309 | ₹730.98₹730.98 | 93.92Average 93.9 Average | 12.27%Average 12.27% Average | 13.33%Average 13.33% Average | 0.39Excellent 0.4 Excellent | 13.76%Good 13.76% Good | 16.16%Excellent 16.16% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1840.00₹1840 | ₹441471.20₹441471.20 | 36.51Average 36.5 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9322.00₹9322 | ₹247033.00₹247033.00 | 84.58Average 84.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4965.50₹4966 | ₹168062.31₹168062.31 | 79.32Average 79.3 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1119.10₹1119 | ₹111686.18₹111686.18 | 24.94Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1366.00₹1366 | ₹110352.31₹110352.31 | 32.73Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1969.00₹1969 | ₹106375.23₹106375.23 | 97.19Average 97.2 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1165.50₹1166 | ₹97319.25₹97319.25 | 30.12Average 30.1 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1679.80₹1680 | ₹96655.69₹96655.69 | 26.25Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2095.00₹2095 | ₹95793.88₹95793.88 | 17.31Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2280.00₹2280 | ₹94164.00₹94164.00 | 46.07Average 46.1 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price441471.20 Cr
- Divi's Laboratories Limited share price247033.00 Cr
- Torrent Pharmaceuticals Limited share price168062.31 Cr
- Zydus Lifesciences Limited share price111686.18 Cr
- Cipla Limited share price110352.31 Cr
Bafna Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for BAFNAPH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹1.76 | ₹150.72 | 85.6x |
| FY 2024 | ₹3.11 | ₹78.90 | 25.4x |
| FY 2023 | ₹4.79 | ₹92.00 | 19.2x |
| FY 2022 | ₹2.21 | ₹100.75 | 45.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Bafna Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for BAFNAPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-23.22%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-97.78%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.16%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
13.76%
Compounded annual net profit growth over 5 years
Bafna Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BAFNAPH — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Bafna Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Bafna Pharmaceuticals Limited (BAFNAPH) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Bafna Pharmaceuticals Limited
About BAFNAPH (Bafna Pharmaceuticals Limited)
Bafna Pharmaceuticals Ltd is a global pharmaceutical company dedicated to the development, manufacturing, and marketing of high-quality finished pharmaceutical formulations. Rooted... in a commitment to innovation and patient well-being, the company focuses on producing a diverse portfolio of medicines designed to address a wide spectrum of therapeutic needs. With a strong emphasis on quality control and adherence to international regulatory standards, Bafna Pharmaceuticals ensures the safety and efficacy of its products. Their manufacturing processes are rigorously monitored, employing state-of-the-art technology to maintain the highest levels of precision and consistency. Bafna Pharmaceuticals has a significant international presence, exporting its pharmaceutical formulations to numerous countries spanning diverse continents. Their extensive distribution network ensures that vital medications reach patients in regions including Europe, Australia, Africa and Asia. This broad reach highlights their dedication to improving global healthcare access and underscores their role as a reliable provider of essential medicines in diverse markets. The company continually strives to strengthen its international partnerships, building collaborative relationships with healthcare providers and distributors to better serve the evolving needs of patients worldwide. Headquartered in Chennai, India, Bafna Pharmaceuticals leverages its strategic location and established infrastructure to drive its operations and maintain its competitive edge. The company benefits from its strong Indian roots while simultaneously embracing a global outlook, fostering a culture of innovation and continuous improvement. As a subsidiary of SRJR Lifesciences LLP, Bafna Pharmaceuticals draws upon the resources and expertise of its parent company, further enhancing its capabilities and supporting its long-term growth objectives within the dynamic pharmaceutical landscape.
Company Details
Key Leadership
BAFNAPH Share Price: Frequently Asked Questions
What is the current share price of Bafna Pharmaceuticals Limited?
Bafna Pharmaceuticals Limited (BAFNAPH) trades at ₹309.00 on NSE and BSE. Market cap ₹730.98 (Cr). Educational data only.
What is the P/E ratio of Bafna Pharmaceuticals Limited?
Bafna Pharmaceuticals Limited has a P/E of 93.92x vs industry average 34.89x.
What is the Bull Run score for Bafna Pharmaceuticals Limited?
Bafna Pharmaceuticals Limited has a Bull Run score of 39.1/100 based on 25+ financial parameters.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Bafna Pharmaceuticals Limited?
Bafna Pharmaceuticals Limited has ROE of 12.27%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bafna Pharmaceuticals Limited?
Bafna Pharmaceuticals Limited has debt-to-equity of 0.39.
Is Bafna Pharmaceuticals Limited a good investment?
Bull Run gives Bafna Pharmaceuticals Limited a score of 39.1/100. This is not investment advice — consult a SEBI-registered advisor.